177 related articles for article (PubMed ID: 15179984)
1. [Immunotherapy for advanced renal cell carcinoma].
Aulitzky WE; Kaufmann M
Urologe A; 2004 Jan; 43(1):85-92; quiz 93. PubMed ID: 15179984
[TBL] [Abstract][Full Text] [Related]
2. Renal cell carcinoma: novel treatments for advanced disease.
Huland E; Heinzer H
Curr Opin Urol; 2003 Nov; 13(6):451-6. PubMed ID: 14560137
[TBL] [Abstract][Full Text] [Related]
3. Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents.
Porta C; Paglino C; Imarisio I; Bonomi L
ScientificWorldJournal; 2007 Apr; 7():837-49. PubMed ID: 17619768
[TBL] [Abstract][Full Text] [Related]
4. The Past, Present and Future of Immunotherapy for Metastatic Renal Cell Carcinoma.
Chang AJ; Zhao L; Zhu Z; Boulanger K; Xiao H; Wakefield MR; Bai Q; Fang Y
Anticancer Res; 2019 Jun; 39(6):2683-2687. PubMed ID: 31177102
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for renal cell cancer in the era of targeted therapy.
Coppin C
Expert Rev Anticancer Ther; 2008 Jun; 8(6):907-19. PubMed ID: 18533800
[TBL] [Abstract][Full Text] [Related]
6. Advances in immune-based therapies of renal cell carcinoma.
Lam JS; Belldegrun AS; Figlin RA
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
[TBL] [Abstract][Full Text] [Related]
7. Recent developments in renal cell cancer immunotherapy.
Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
Expert Opin Biol Ther; 2007 May; 7(5):727-37. PubMed ID: 17477809
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
[TBL] [Abstract][Full Text] [Related]
9. New therapeutic developments in renal cell cancer.
Prenen H; Gil T; Awada A
Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
[TBL] [Abstract][Full Text] [Related]
10. Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?
Di Nunno V; Gatto L; Fragomeno B; Cubelli M; Nobili E; Romano I; Santoni M; Pisconti S; Montironi R; Massari F
Future Oncol; 2018 Dec; 14(29):2997-2999. PubMed ID: 30411632
[No Abstract] [Full Text] [Related]
11. [Therapy strategies for advanced renal cell carcinoma].
Staehler M; Haseke N; Schöppler G; Stadler T; Adam C; Stief CG
Urologe A; 2006 Jan; 45(1):99-110, quiz 111-2. PubMed ID: 16372186
[TBL] [Abstract][Full Text] [Related]
12. Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Ramsey S; Aitchison M
J Urol; 2005 Dec; 174(6):2422-3. PubMed ID: 16280863
[No Abstract] [Full Text] [Related]
13. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
May M; Helke C; Bock M; Hoschke B
Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
[TBL] [Abstract][Full Text] [Related]
14. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
Parton M; Gore M; Eisen T
J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
[TBL] [Abstract][Full Text] [Related]
15. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
17. [Systemic therapy of metastatic renal cell carcinoma].
Autenrieth M; Heidenreich A; Gschwend JE
Urologe A; 2006 May; 45(5):594-9. PubMed ID: 16622645
[TBL] [Abstract][Full Text] [Related]
18. What advances have been made in immune-therapy for renal cell carcinoma?
Verzoni E; Grassi P; Ratta R
Future Oncol; 2017 Apr; 13(8):665-668. PubMed ID: 28183189
[No Abstract] [Full Text] [Related]
19. Combination of surgery and immunotherapy in metastatic renal cell carcinoma.
Mickisch GH; Mattes RH
World J Urol; 2005 Jul; 23(3):191-5. PubMed ID: 15791469
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
McDermott DF; Regan MM; Atkins MB
Clin Genitourin Cancer; 2006 Sep; 5(2):114-9. PubMed ID: 17026799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
